Evaluation of a recombinant tetanus toxin subunit vaccine.
Ganglioside
Immunogenicity
Receptor-binding domain
Recombinant vaccine
Tetanus
Journal
Toxicon : official journal of the International Society on Toxinology
ISSN: 1879-3150
Titre abrégé: Toxicon
Pays: England
ID NLM: 1307333
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
27
05
2020
revised:
30
07
2020
accepted:
03
08
2020
pubmed:
6
9
2020
medline:
5
11
2020
entrez:
5
9
2020
Statut:
ppublish
Résumé
Tetanus is an acute, fatal disease caused by exotoxin produced by Clostridium tetani. The current vaccine against tetanus is based on inactivated tetanus toxin (TeNT). To develop a recombinant TeNT vaccine suitable for replacement of full-length tetanus toxoid (TT) vaccine for use in humans, a recombinant non-tagged isoform of the Hc domain of the tetanus toxin (THc) was expressed in Escherichia coli and purified by sequential chromatography steps. The immunogenicity and protective effect of the THc antigen were explored and compared with those of TT in Balb/c mice. The THc-based subunit vaccine provided complete protection against TeNT challenge following a high dosage as a toxoid vaccine. While the anti-THc and neutralising antibody titres were higher for the THc-based vaccine than the TT vaccine because protective epitopes are located on the THc domain. Frequency- and dose-dependent immunoprotection were also observed in THc-immunised mice. Mice immunised with one injection of 1 μg or 4 μg THc antigen were completely protected against 10
Identifiants
pubmed: 32889026
pii: S0041-0101(20)30341-X
doi: 10.1016/j.toxicon.2020.08.001
pii:
doi:
Substances chimiques
Antibodies, Neutralizing
0
Gangliosides
0
Tetanus Toxin
0
Tetanus Toxoid
0
Vaccines, Subunit
0
Vaccines, Synthetic
0
trisialoganglioside GT1
59247-13-1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
75-81Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.